Lung and Chest Pain: Perception and Mechanisms in the Absence of Nerves

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.16" custom_padding="|||" global_colors_info="{}" custom_padding__hover="|||" theme_builder_area="post_content"][et_pb_image src="https://aspergillosis.org/wp-content/uploads/2023/04/AdobeStock_303540715.jpeg" _builder_version="4.20.4" _module_preset="default" theme_builder_area="post_content" title_text="Isolated vector illustration of the human bowel with small bowel and colon." hover_enabled="0" sticky_enabled="0" align="center" width="18%"][/et_pb_image][et_pb_text _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"]

When we think of pain, we often associate it with injury or damage to a particular part of our body. However, the experience of pain is not always straightforward, especially when it comes to the lungs, as they have very few nerve endings compared to other parts of the body. This post aims to shed light on the mechanisms of lung and chest pain, including cardiac causes, and how lung pain is felt despite having very few nerves.

The Perception of Pain

Pain serves as a protective mechanism that alerts the body to potential harm. It is a complex process involving the nervous system, which includes peripheral nerves, the spinal cord, and the brain. Pain perception typically begins with the activation of nociceptors, which are specialised nerve endings that initiate the response to pain from stimuli. These nerve endings transmit signals through the peripheral nerves to the spinal cord and, ultimately, to the brain, where the sensation of pain is processed and perceived.

The Autonomic Nervous System

The autonomic nervous system is part of the nervous system that controls involuntary functions within the body, such as heart rate, blood pressure, digestion, breathing, and temperature regulation. It operates mostly unconsciously, allowing your body to automatically respond and adapt to changes in the environment and maintain a stable internal state, known as homeostasis. The sympathetic and parasympathetic nerves are part of the autonomic nervous system, which controls involuntary functions in your body.

The sympathetic nerves are responsible for the 'fight or flight' response, preparing your body for action during times of stress. They increase heart rate, blood pressure, and breathing rate.

The parasympathetic nerves help your body relax and recover, promoting the rest and digest response. They lower heart rate and blood pressure and facilitate digestion. Together, these nerves help maintain balance in your body, ensuring it responds appropriately to different situations.

Lung Anatomy and Nerve Distribution

Unlike the skin and muscles, the lungs have a relatively sparse distribution of nerve endings. The majority of nerves in the lungs are part of the autonomic nervous system. The lungs are primarily innervated by the vagus nerve, which carries sensory information from the lungs to the brain. The sympathetic and parasympathetic nerves regulate bronchial smooth muscle tone and mucus secretion.

Pain in the Lungs and Chest: Mechanisms and Causes

Despite having very few nociceptors (pain receptors), it is still possible to experience pain in the lungs and chest. This pain can be a result of various factors, including:

  • Pleural irritation: The lungs are surrounded by a double-layered membrane called the pleura. The pleura contains nociceptors that can become irritated by inflammation or infection, resulting in pleuritic pain – a sharp, stabbing sensation felt in the chest, which typically worsens with deep breathing or coughing.
  • Referred pain: The brain can sometimes misinterpret signals from the lungs or pleura, perceiving pain in nearby areas such as the chest, back, or shoulders. This is known as referred pain and can result from lung conditions like pneumonia, pleurisy, or pulmonary embolism.
  • Bronchospasm: Constriction of the bronchial muscles can lead to a sensation of chest tightness and difficulty breathing, which may be perceived as pain.
  • Lung tissue damage: Although the lung tissue itself has few nociceptors, severe inflammation or infection can cause damage to the surrounding tissues, leading to the perception of pain.
  • Cardiac causes: Chest pain can also be a symptom of heart-related issues, such as angina or a heart attack. Pain from cardiac causes is often described as a pressure, tightness, or squeezing sensation in the chest. It can sometimes radiate to the arms, neck, jaw, or back. It is essential to seek immediate medical attention if you suspect your chest pain is heart-related.

Please note the above list is not exhaustive. If you are experiencing pain that is new for you, has not been investigated or is in any way different from your usual symptoms - please seek medical advice.

Further reading on lung conditions not related to aspergillosis can be found via the following resources:

  • British Lung Foundation: A UK-based charity that offers extensive information on various lung conditions, their symptoms, and available treatments. Visit their website at https://www.blf.org.uk/ for patient guides and support.
  • Asthma UK: A charity focused on helping people with asthma understand and manage their condition. Their website (https://www.asthma.org.uk/) offers information on asthma symptoms, triggers, treatments, and personal stories from patients.
  • COPD Foundation: A non-profit organisation dedicated to improving the lives of those affected by chronic obstructive pulmonary disease (COPD). Their website (https://www.copdfoundation.org/) provides a wealth of information on COPD, including educational materials, management strategies, and support groups.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]


NAC CARES Virtual Challenge - 803 miles (1292.41 km) down

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.16" custom_padding="|||" global_colors_info="{}" custom_padding__hover="|||" theme_builder_area="post_content"][et_pb_text _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"]

It's been a couple of weeks since our last update, and we're excited to share our progress on our team's virtual Lands End to John O'Groats challenge. As most of you may know, we embarked on this journey to walk, cycle, and run the length of the UK to raise money for the Fungal Infection Trust. Despite the Easter holidays, we haven't stopped and are mostly being fueled by Easter eggs right now!

We have now covered a total of 1292.41km (802.6 miles), which is 74% of the distance, in only 67% of the planned time of 100 days. This puts us well ahead of schedule, with just 451.79km (280.6 miles) remaining in our challenge.

Currently, we are in Scotland and approaching the iconic Forth Bridge. Along the way, we have passed several historic landmarks, including:

Hadrian's Wall: A UNESCO World Heritage Site, this ancient Roman fortification stretches for 73 miles (117 km) across the North of England from the west coast of Cumbria near the Solway Firth to the east coast near the River Tyne in Tyne and Wear. Constructed in AD 122 under Emperor Hadrian's rule, the wall was designed to separate Roman Britain from the barbarian north and served as a military defence line.

Edinburgh Castle: Perched on an extinct volcano, this historic fortress dominates the skyline of Scotland's capital city. With its origins dating back to the 12th century, the castle has been a royal residence, a military garrison, and a prison over the years. Today, it serves as a popular tourist attraction and houses the Scottish Crown Jewels and the Stone of Destiny, also known as the Stone of Scone or the Coronation Stone, which is a historic and symbolic block of red sandstone, measuring approximately 26 inches (66 cm) in length, 16 inches (40 cm) in width, and 11 inches (28 cm) in depth.

Our accelerated pace is down to our team's hard work and dedication. We are making excellent progress in our challenge, but we still have a significant distance to cover to reach John O'Groats and our fundraising goal. We are grateful for your support and are confident that, together, we will make a difference in the fight against fungal infections.

Thank you for following us on this journey; we look forward to sharing more updates with you soon. You can donate via the link below.

https://www.justgiving.com/campaign/LEJOG-for-Aspergillosis

[/et_pb_text][et_pb_gallery _builder_version="4.20.4" _module_preset="default" theme_builder_area="post_content" gallery_ids="9960,9959,9958" show_title_and_caption="off" hover_enabled="0" sticky_enabled="0"][/et_pb_gallery][/et_pb_column][/et_pb_row][/et_pb_section]


The Benefits of Peer Support

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.16" custom_padding="|||" global_colors_info="{}" custom_padding__hover="|||" theme_builder_area="post_content"][et_pb_text _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"]

Living with chronic and rare conditions such as chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA) can be a daunting experience. The symptoms of these conditions can be severe and have a significant impact on a person's daily life. The journey can be lonely and isolating, and it's common to feel like no one understands what you're going through. This is where peer support can be incredibly valuable.

Peer support is a way for people with a shared experience to connect and share their stories, advice, and coping strategies. It can be offered in various forms, including online support groups, peer mentoring programs, and in-person support groups. It allows people to feel understood, validated, and supported in a way that other forms of support cannot offer.

At the National Aspergillosis Centre (NAC), we understand the importance of peer support for people living with aspergillosis. While we offer advice and guidance on how to manage your condition, we recognise that much of the support comes from those with a lived experience of the condition.

Our virtual patient and carer support meetings are an excellent example of peer support in action. These meetings are hosted on Microsoft Teams twice a week and are open to everyone, not just those who are patients of NAC. These meetings provide a safe and supportive space for people to connect with others who understand what they're going through. They allow people to share their experiences, ask questions, and learn from others who have lived with the condition for a longer period.

Through these meetings, patients gain insight into coping mechanisms and strategies that help others live as normal a life as possible with their condition. We have seen many of our patients build lasting friendships with people who understand what they're going through.

So, if you are living with any type of aspergillosis, our peer support channels can be a valuable resource. Connecting with others who share your experience can provide benefits that are difficult to achieve through other forms of support. Our virtual patient and carer support meetings are an excellent place to start, and we encourage you to join us and see the benefits of peer support for yourself.

You can find out the details and sign up for our meetings by clicking here.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]


2023 Bronchiectasis Patient Conference

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.16" custom_padding="|||" global_colors_info="{}" custom_padding__hover="|||" theme_builder_area="post_content"][et_pb_text _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"]

The 2023 Bronchiectasis Patient Conference, organised by the European Lung Foundation, is a popular event for patients each year. This year we asked two of our patients who attended to share their personal experiences and thoughts on the conference, highlighting its importance and impact.

Our patients reported that the conference attracted 1,750 registrations from 90 countries, and during an online questionnaire, 47% of participants identified as living with bronchiectasis. Dr Fiona Mosgrove's presentation on "Living with Bronchiectasis" provided valuable insights on lifestyle, nutrition, and mental health, recommending two books for further reading.

Prof. James Chalmers discussed a potential new treatment involving an anti-pseudomonas monoclonal antibody, demonstrated through engaging video clips. The conference also covered other topics such as Phage therapy, bronchiectasis through different life stages, and the importance of end-of-life care discussions.

Both patients found the conference to be an informative and valuable experience, despite facing some technical difficulties and unclear presentations due to those difficulties. They appreciated Dr Chalmers' well-paced talk on new treatments, as well as Dr Mosgrove's discussion on mental health and airway clearance techniques. One patient noted that while coexisting diseases like chronic obstructive pulmonary disease (COPD) and asthma were mentioned, there was no reference to Aspergillosis. The conference emphasised the importance of daily airway clearance, exercise, relaxation, and ongoing research for more effective treatments.

In summary, both patients found the 2023 Bronchiectasis Patient Conference to be an enriching experience, providing valuable insights and practical takeaways for managing the condition. Despite some technical issues, the conference succeeded in raising awareness and fostering a sense of community among people living with bronchiectasis.

[/et_pb_text][et_pb_video src="https://www.youtube.com/watch?v=ophaiwZ6rew" _builder_version="4.20.2" _module_preset="default" theme_builder_area="post_content" hover_enabled="0" sticky_enabled="0"][/et_pb_video][/et_pb_column][/et_pb_row][/et_pb_section]


NAC CARES Virtual Challenge – 587.5 miles (945.11 km down)

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.16" custom_padding="|||" global_colors_info="{}" custom_padding__hover="|||" theme_builder_area="post_content"][et_pb_text _builder_version="4.20.2" background_size="initial" background_position="top_left" background_repeat="repeat" hover_enabled="0" global_colors_info="{}" theme_builder_area="post_content" sticky_enabled="0"]
We are excited to share with you an update on our team's virtual Lands End to John O'Groats challenge. As you may know, our team is walking, cycling, and running the length of the UK to raise money for the Fungal Infection Trust. We are proud to announce that we have completed 54% of the challenge, which is equivalent to 945.11km or 587.5 miles.

Currently, we are virtually passing through the breathtaking Yorkshire Dales National Park, having already passed through several noteworthy locations on our journey. These include:

    • Bradford: A vibrant city located in West Yorkshire, known for its industrial history and impressive Victorian architecture.
    • Huddersfield: A bustling town with a rich cultural heritage, including notable landmarks such as Castle Hill and St. George's Square.
    • The Peak District National Park: A stunning area of natural beauty spanning across several counties, including Derbyshire, Cheshire, and Staffordshire. It's famous for its dramatic landscapes, rugged moorlands, and picturesque villages.
    • Sheffield: A vibrant city known for its steel industry, green spaces, and cultural landmarks such as the Millennium Gallery and Winter Garden.
    • Sherwood Forest: A legendary location associated with Robin Hood and his band of merry men, known for its ancient oaks and rich wildlife.
    • Rufford Abbey: A former Cistercian monastery located in Sherwood Forest, which is now a popular tourist attraction featuring a country park and gardens.
    • Sherwood Pines Forest Park: A sprawling woodland park with a range of outdoor activities, including cycling, walking, and a Go Ape treetop adventure course.
    • Robin Hood's Wheelgate Park: A family-friendly theme park featuring a range of rides, attractions, and live shows.
    • Nottingham: A historic city with a rich cultural heritage, including landmarks such as Nottingham Castle, the Old Market Square, and the Lace Market.

We are thrilled to have made it this far, and we are well ahead of schedule. We are grateful for your continued support, but we still have a long way to go to reach our fundraising goal and John O' Groats; we are confident both will be achieved, and with it, we will make a difference in the fight against fungal infections.

Thank you for joining us on this journey, and we look forward to sharing more updates with you soon. You can donate via the link below.

https://www.justgiving.com/campaign/LEJOG-for-Aspergillosis

 

 


[/et_pb_text][et_pb_gallery gallery_ids="9860,9859,9858,9857,9856,9861" posts_number="6" show_title_and_caption="off" show_pagination="off" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_gallery][/et_pb_column][/et_pb_row][/et_pb_section]


Fungal vaccine developments

[et_pb_section fb_built="1" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.20.2" _module_preset="default" custom_margin="3px|auto|3px|auto|true|false" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"]
The numbers of people at risk of fungal infections are increasing due to an aging population, increased use of immunosuppressive medications, pre-existing medical conditions, environmental changes, and lifestyle factors. Therefore, there is a growing need for new treatments or preventative options.

Current treatment options for fungal infections often involve the use of antifungal medications, such as azoles, echinocandins, and polyenes. These medications are generally effective in treating fungal infections, but they can have drawbacks. For example, some antifungal drugs can interact with other medications, leading to potentially harmful side effects. Additionally, overuse of antifungal drugs can contribute to the development of antifungal drug resistance, which can make treatment more challenging.

There has been a growing interest in the development of fungal vaccines as an alternative treatment. A fungal vaccine works by stimulating the immune system to produce a specific response against the fungus, which can provide long-term protection against infection. The vaccine could be given to at-risk individuals before exposure to the fungus, preventing infection from occurring in the first place.
[/et_pb_text][et_pb_text _builder_version="4.22.2" _module_preset="624b8eae-e2e0-40f4-a48e-83d57e3006b6" theme_builder_area="post_content" hover_enabled="0" sticky_enabled="0"]
A recent study by researchers from the University of Georgia demonstrated the potential for a pan-fungal vaccine to protect against multiple fungal pathogens, including those that cause aspergillosis, candidiasis, and pneumocystosis. The vaccine, called NXT-2, was designed to stimulate the immune system to recognize and fight against several types of fungi.

The study found that the vaccine was able to induce a strong immune response in mice and additionally protect them from infection with several different fungal pathogens, including Aspergillus fumigatus, which is the main cause of aspergillosis. The vaccine was found to be safe and well-tolerated in the mice, with no adverse effects reported.

This study demonstrates the potential for a pan-fungal vaccine to protect against multiple fungal pathogens. While the study did not specifically address the use of the vaccine in patients with pre-existing aspergillosis infections, the findings suggest that the vaccine has potential to prevent aspergillosis infection in high-risk individuals.
[/et_pb_text][et_pb_text _builder_version="4.22.2" _module_preset="default" theme_builder_area="post_content" hover_enabled="0" sticky_enabled="0"]
In summary, while the development of antifungal vaccines offers a promising potential alternative to the challenges posed by current treatment options for fungal infections, further research is needed to determine the safety and efficacy of the vaccine in humans, including those with aspergillosis, before it can be considered as a treatment option.

Original paper: https://academic.oup.com/pnasnexus/article/1/5/pgac248/6798391?login=false 
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]


Asthma UK's End the Lung Health Lottery


[et_pb_row][et_pb_column type="4_4"][et_pb_text]

Today is the launch of Asthma UK's End the Lung Health Lottery campaign. The initiative seeks to address the significant health inequalities that exist across the UK and highlights the fact that where people live, their income and their social status can have a significant impact on their lung health, with those from disadvantaged communities being at a much higher risk of developing lung conditions.

The campaign's main objective is to end the "lung health lottery" and ensure that everyone has equal access to high-quality care and support for lung conditions, regardless of their background or where they live. In order to tackle the issue, Asthma UK is working with healthcare professionals, policymakers, and other organisations to achieve this goal.

The campaign aims to address the root causes of lung health inequalities, such as poverty, air pollution, and lack of access to healthcare, and empower people to take control of their lung health. Asthma UK is calling for more funding for research and initiatives that can help tackle these issues, as well as more investment in public health campaigns to raise awareness of the importance of lung health.

Through the End the Lung Health Lottery campaign, Asthma UK hopes to create a fairer and more equal society for people with lung conditions. By working together, we can improve the lives of millions of people across the UK and ensure that no one is left behind because of their background or where they live. You can read more about the campaign below and pledge your support via the link below.

https://www.asthmaandlung.org.uk/end-lung-health-lottery?utm_source=Twitter&utm_medium=Social&utm_campaign=Lottery&utm_id=#get-support

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]


Secondary Adrenal Insufficiency

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.16" custom_padding="|||" global_colors_info="{}" custom_padding__hover="|||" theme_builder_area="post_content"][et_pb_text _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}" theme_builder_area="post_content"]

This month's (March) patient meeting included a presentation by Endocrinology Specialist Nurses from Manchester Royal Infirmary. This was a talk we requested as we know secondary adrenal insufficiency is a concern for many patients.

 Allergic bronchopulmonary aspergillosis (ABPA) is a complex respiratory condition that occurs when the immune system overreacts to the Aspergillus fungus, leading to inflammation and potential lung damage. To manage the symptoms of ABPA, patients are often prescribed corticosteroid medications. However, long-term use of these medications can lead to a condition called secondary adrenal insufficiency. Watch the talk below to learn more about the condition, it's diagnosis, management and treatment. 

 

 

[/et_pb_text][et_pb_video src="https://youtu.be/W6RLUeOjUrw" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_video][/et_pb_column][/et_pb_row][/et_pb_section]


Virtual Support Meetings Moving from Zoom to Microsoft Teams

[et_pb_section fb_built="1" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.20.2" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.20.2" _module_preset="default" hover_enabled="0" global_colors_info="{}" theme_builder_area="post_content" sticky_enabled="0"]

We will, in the coming weeks, be moving our virtual patient support meetings from the Zoom platform to Microsoft Teams. The NAC Cares Team understands that for some, this is an unfamiliar application, and the change can be daunting. We will be assisting in this transition and helping guide people by utilising both platforms.

Microsoft Teams is a powerful tool that offers all the same features as Zoom. Here's a step-by-step guide on how to attend the meeting as a guest:

The meeting link works in a similar way to Zoom, and you can register for a link through Eventbrite. If you have any issues, you can contact the CARES Team at [email protected]

Clinking the link will open a web page, where you'll see two choices: Download the Windows app and Join on the web instead. If you join on the web, we advise the use of Google Chrome. Your browser may ask if it's okay for Teams to use your mic and camera. Be sure to allow it so you'll be seen and heard in your meeting.

If you want to install Microsoft Teams on your device, you can follow the prompts and on-screen instructions. Once the app is installed, enter your name and choose your audio and video settings and then hit join now.

If you enter the meeting lobby, wait for one of the CARES Team to admit you.

During the meeting:

  • Once you've joined the meeting, you'll be able to see and hear the other patients/relatives.
  • You can choose to turn on or off your camera and microphone by selecting the camera or microphone icons at the bottom of the screen.
  • There is a chat function to send messages to other participants.

Leaving the meeting:

To leave the meeting, select the "Leave" button at the top-right corner of the screen.

If you wish to download Microsoft Teams you can do so via the link below:

https://www.microsoft.com/en-us/microsoft-teams/download-app

 


[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]


IgG and IgE explained


[et_pb_row][et_pb_column type="4_4"][et_pb_text]

Immunoglobulins, also known as antibodies, are proteins produced by the immune system in response to the presence of foreign substances, such as viruses and bacteria. There are different types of immunoglobulins, including IgG and IgE, which play different roles in the immune system. In aspergillosis, both IgG and IgE antibodies play important roles in the immune response to the Aspergillus fungus. This post aims to provide important information about the differences between IgG and IgE.

What is IgG?

IgG is the most common type of immunoglobulin in the bloodstream, accounting for about 75% of all antibodies in the body. IgG plays an important role in fighting off bacterial and viral infections and is also involved in the immune response to certain types of cancer cells. IgG can cross the placenta and provide protection to a developing foetus, which is why it is referred to as a "maternal antibody."

Elevated levels of IgG antibodies to Aspergillus are often seen in individuals with Chronic Pulmonary Aspergillosis (CPA), and measuring IgG antibody levels is an important diagnostic tool for the condition.

What is IgE?

IgE is a type of immunoglobulin that plays a role in the allergic response. IgE is produced in response to exposure to allergens, such as pollen, pet hair, and certain food, and for patients with allergic bronchopulmonary aspergillosis - aspergillus fungus. When IgE binds to an allergen, it triggers the release of histamine and other chemicals, leading to the symptoms of an allergic reaction, such as:

  • Wheezing
  • Coughing
  • Shortness of breath
  • Chest pain or tightness

Differences between IgG and IgE

There are several differences between IgG and IgE, including:

  • IgG plays a role in fighting off bacterial and viral infections, while IgE is involved in the allergic response.
  • IgG has a longer half-life in the bloodstream than IgE, which means it stays in the body longer.
  • IgG takes longer to produce in response to an infection or exposure to an antigen, while IgE is produced rapidly in response to an allergen.

Both IgG and IgE antibodies play important roles in the immune response in aspergillosis. While IgG helps to neutralise and eliminate the fungus, IgE triggers the allergic response and leads to symptoms in individuals with Allergic Bronchopulmonary Aspergillosis (ABPA). Measuring antibody levels to Aspergillus can be helpful in diagnosing and monitoring these conditions.

More information on the role of IgE and IgG can be found via the links below:

https://onlinelibrary.wiley.com/doi/10.1111/all.14908

https://www.britannica.com/science/immune-system/Classes-of-immunoglobulins

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]